Form 4 for ANIP ANI PHARMACEUTICALS INC
Accepted 2026-08-26 18:15:10 ET · period of report 2026-08-25 · accession 0001822629-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-26 18:15 | 2026-08-25 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale | $74.30 | -5,400 | 344.5K | -2% | -$401.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-25 | S | D | 5,400 | $74.30 | 344,489 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. (F2) The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price. |